Pan-India Ayurveda hospital/clinic operator ('Shuddhi') with a ~330-SKU Ayurvedic products business.
Price
Market Cap
Sector
Consumer Discretionary
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 0 | 0 | 10 | 14 | 25 | 25 | 25 | 25 |
| Reserves | 14 | 24 | 26 | 112 | 167 | 231 | 329 | 442 |
| Borrowings | 12 | 12 | 7 | 1 | 1 | 117 | 106 | 127 |
| Other Liabilities | 12 | 13 | 18 | 24 | 28 | 46 | 86 | 80 |
| Total Liabilities | 38 | 49 | 62 | 151 | 221 | 419 | 546 | 674 |
| AssetsFixed Assets | 17 | 23 | 29 | 60 | 67 | 255 | 261 | 294 |
| CWIP | 0 | 0 | 5 | 1 | 4 | 11 | 17 | 2 |
| Investments | 0 | 0 | 0 | 5 | 4 | 4 | 92 | 110 |
| Other Assets | 21 | 26 | 28 | 86 | 146 | 149 | 176 | 269 |
| Total Assets | 38 | 49 | 62 | 151 | 221 | 419 | 546 | 674 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 1 | 12 | 18 | 16 | 15 | 37 | 84 | 254 |
| Cash from Investing | -11 | -6 | -8 | -18 | -33 | -18 | -64 | -202 |
| Cash from Financing | 7 | -5 | -2 | -5 | 48 | -3 | -22 | -59 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -10 | 6 | 9 | -2 | -15 | 23 | 45 | 221 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (45.6×) and current (31.2×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 174.1% growth and a 31× exit, ₹557 only delivers your return if you pay ₹64,802. The price is currently baking in 18% growth.
EPS grows 174.1%/yr for 5 years, then fades to 6% over 2, exits at 31×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 174.1% | 48.90 |
| FY28 | 174.1% | 134.03 |
| FY29 | 174.1% | 367.39 |
| FY30 | 174.1% | 1007.00 |
| FY31 | 174.1% | 2760.20 |
| FY32 | 90.0% ·fade | 5245.75 |
| FY33 | 6.0% ·fade | 5560.50 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.